Based on TCGA data, ccRCC patients with high SPON2 mRNA had a significantly worse overall survival (OS) probability than those with low SPON2 mRNA (Log-rank test, P = 0.0016; Figure 4(b)). This evidence concerns the gene SPON2 and nonpapillary renal cell carcinoma.